Bibliography

Found 15 results

Filters: Keyword is Viral Load and Author is Letendre, Scott L [Clear All Filters]

2019

Anderson AM, Pérez-Santiago J, Zheng Z, Huang E, Franklin D, Iudicello J, Moore DJ, Ellis RJ, Heaton RK, Letendre SL. Better executive function is independently associated with full HIV suppression during combination therapy. AIDS. 2019 ;33(15):2309-2316.

Livelli A, Vaida F, Ellis RJ, Ma Q, Ferrara M, Clifford DB, Collier AC, Gelman B, Marra CM, McArthur JC, et al. Correlates of HIV RNA concentrations in cerebrospinal fluid during antiretroviral therapy: a longitudinal cohort study. Lancet HIV. 2019 ;6(7):e456-e462.

2017

Patton SM, Wang Q, Hulgan T, Connor JR, Jia P, Zhao Z, Letendre SL, Ellis RJ, Bush WS, Samuels DC, et al. Cerebrospinal fluid (CSF) biomarkers of iron status are associated with CSF viral load, antiretroviral therapy, and demographic factors in HIV-infected adults. Fluids Barriers CNS. 2017 ;14(1):11.

Anderson AM, Muñoz-Moreno JA, McClernon DR, Ellis RJ, Cookson D, Clifford DB, Collier AC, Gelman BB, Marra CM, McArthur JC, et al. Prevalence and Correlates of Persistent HIV-1 RNA in Cerebrospinal Fluid During Antiretroviral Therapy. J Infect Dis. 2017 ;215(1):105-113.

2015

Clifford DB, Vaida F, Kao Y-ting, Franklin D, Letendre S, Collier AC, Marra CM, Gelman B, McArthur JC, Morgello S, et al. Absence of neurocognitive effect of hepatitis C infection in HIV-coinfected people. Neurology. 2015 ;84(3):241-50.

Bryant AK, Ellis RJ, Umlauf A, Gouaux B, Soontornniyomkij V, Letendre SL, Achim CL, Masliah E, Grant I, Moore DJ. Antiretroviral therapy reduces neurodegeneration in HIV infection. AIDS. 2015 ;29(3):323-30.

2014

Grant I, Franklin D, Deutsch R, Woods SPaul, Vaida F, Ellis RJ, Letendre S, Marcotte TD, Atkinson JH, Collier AC, et al. Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline. Neurology. 2014 ;82(23):2055-62.

Letendre SL, Mills AM, Tashima KT, Thomas DA, Min SS, Chen S, Song IH, Piscitelli SC. ING116070: a study of the pharmacokinetics and antiviral activity of dolutegravir in cerebrospinal fluid in HIV-1-infected, antiretroviral therapy-naive subjects. Clin Infect Dis. 2014 ;59(7):1032-7.

2011

Jernigan TL, Archibald SL, Fennema-Notestine C, Taylor MJ, Theilmann RJ, Julaton MD, Notestine RJ, Wolfson T, Letendre SL, Ellis RJ, et al. Clinical factors related to brain structure in HIV: the CHARTER study. J Neurovirol. 2011 ;17(3):248-57.

Best BM, Koopmans PP, Letendre SL, Capparelli EV, Rossi SS, Clifford DB, Collier AC, Gelman BB, Mbeo G, J McCutchan A, et al. Efavirenz concentrations in CSF exceed IC50 for wild-type HIV. J Antimicrob Chemother. 2011 ;66(2):354-7.

Moore DJ, Letendre SL, Morris S, Umlauf A, Deutsch R, Smith DM, Little S, Rooney A, Franklin DR, Gouaux B, et al. Neurocognitive functioning in acute or early HIV infection. J Neurovirol. 2011 ;17(1):50-7.

2009

Best BM, Letendre SL, Brigid E, Clifford DB, Collier AC, Gelman BB, McArthur JC, J McCutchan A, Simpson DM, Ellis R, et al. Low atazanavir concentrations in cerebrospinal fluid. AIDS. 2009 ;23(1):83-7.

Gongvatana A, Schweinsburg BC, Taylor MJ, Theilmann RJ, Letendre SL, Alhassoon OM, Jacobus J, Woods SP, Jernigan TL, Ellis RJ, et al. White matter tract injury and cognitive impairment in human immunodeficiency virus-infected individuals. J Neurovirol. 2009 ;15(2):187-95.

2006

de Almeida SM, Letendre S, Ellis RJ. Human immunodeficiency virus and the central nervous system. The Brazilian Journal of Infectious Diseases: An Official Publication of the Brazilian Society of Infectious Diseases [Internet]. 2006 ;10:41-50. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16767315

Langford D, Marquie-Beck J, de Almeida SM, Lazzaretto D, Letendre S, Grant I, McCutchan JA, Masliah E, Ellis RJ. Relationship of antiretroviral treatment to postmortem brain tissue viral load in human immunodeficiency virus-infected patients. Journal of Neurovirology [Internet]. 2006 ;12:100-7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16798671